Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-EX02 CAR T cells
- Development stage
- Phase 1
- Lead developer
- Zeno Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-EX02 CAR T cells are an autologous chimeric antigen receptor (CAR) T cell therapy developed by Zeno Therapeutics. This investigational therapy involves engineering a patient's own T lymphocytes to express a synthetic receptor (CAR) that targets the EX02 antigen, which is associated with certain solid tumors and hematologic malignancies. The modified T cells are expanded ex vivo and reinfused into the patient to mediate targeted immunologic cytotoxicity against tumor cells expressing the EX02 antigen. The primary mechanism of action is direct killing of cancer cells via recognition and engagement of the target antigen by engineered CARs on patient-derived cytotoxic T lymphocytes. Anti-EX02 CAR-T is being studied for use in relapsed/refractory acute myeloid leukemia as well as advanced pancreatic and bile duct cancers[1][2][3].
- Other names
- Anti EX02 chimeric antigen receptor T cell therapy
02
Targets
SRRM2 (Serine/arginine repetitive matrix protein 2)
Beyond the preview
Go deeper on anti-EX02 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-EX02 CAR T cells.